Works matching DE "OVERALL survival"

Results: 5000
    1
    2
    3
    4
    5
    6
    7

    Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ductal adenocarcinoma.

    Published in:
    BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14283-w
    By:
    • Pedersen, Rasmus S.;
    • Hettich, Annika;
    • Thorlacius-Ussing, Jeppe;
    • Langholm, Lasse L.;
    • Crespo-Bravo, Marina;
    • Chen, Inna M.;
    • Hansen, Carsten P.;
    • Johansen, Julia S.;
    • Diab, Hadi M. H.;
    • Jorgensen, Lars N.;
    • Karsdal, Morten;
    • Willumsen, Nicholas
    Publication type:
    Article
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17

    Dilemmas in precise prognosis.

    Published in:
    Journal of Dental Specialities, 2025, v. 13, n. 1, p. 1, doi. 10.18231/j.jds.2025.001
    By:
    • Shetty, Devi Charan
    Publication type:
    Article
    18
    19
    20
    21
    22

    Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ductal adenocarcinoma.

    Published in:
    BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14283-w
    By:
    • Pedersen, Rasmus S.;
    • Hettich, Annika;
    • Thorlacius-Ussing, Jeppe;
    • Langholm, Lasse L.;
    • Crespo-Bravo, Marina;
    • Chen, Inna M.;
    • Hansen, Carsten P.;
    • Johansen, Julia S.;
    • Diab, Hadi M. H.;
    • Jorgensen, Lars N.;
    • Karsdal, Morten;
    • Willumsen, Nicholas
    Publication type:
    Article
    23
    24

    Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2025, v. 44, n. 1, p. 1, doi. 10.1186/s13046-025-03406-7
    By:
    • Hou, Xiaonan;
    • Zanfagnin, Valentina;
    • Xu, Conway;
    • Jessen, Erik;
    • Liu, Yuanhang;
    • Wang, Chen;
    • Huang, Yajue;
    • Fontaine, Shaun D.;
    • Santi, Daniel V.;
    • Colon-Otero, Gerardo;
    • Gill, Sarah E.;
    • Glaser, Gretchen E.;
    • Butler, Kristina A.;
    • Bakkum-Gamez, Jamie N.;
    • Dowdy, Sean C.;
    • Oberg, Ann L.;
    • Larson, Melissa C.;
    • Atkinson, Hunter J.;
    • Duffield, Laura N.;
    • Peterson, Kevin L.
    Publication type:
    Article
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41

    The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world setting.

    Published in:
    British Journal of Dermatology, 2025, v. 192, n. 6, p. 1096, doi. 10.1093/bjd/ljae470
    By:
    • Billard, Karine;
    • Mortier, Laurent;
    • Dereure, Olivier;
    • Dalac, Sophie;
    • Montaudié, Henri;
    • Legoupil, Delphine;
    • Dutriaux, Caroline;
    • Quatrebarbes, Julie De;
    • Maubec, Eve;
    • Leccia, Marie-Thérèse;
    • Granel-Brocard, Florence;
    • Brunet-Possenti, Florence;
    • Arnault, Jean-Philippe;
    • Gaudy-Marqueste, Caroline;
    • Pages, Cecile;
    • Saiag, Philippe;
    • L'Orphelin, Jean-Matthieu;
    • Zehou, Ouidad;
    • Lesimple, Thierry;
    • Allayous, Clara
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48

    Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-59744-9
    By:
    • Arrieta, Oscar;
    • Lara-Mejía, Luis;
    • Rios-Garcia, Eduardo;
    • Caballé-Perez, Enrique;
    • Cabrera-Miranda, Luis;
    • Ramos-Ramírez, Maritza;
    • Dávila-Dupont, David;
    • Cardona, Andrés F.;
    • Cruz-Rico, Graciela;
    • Remon, Jordi;
    • Garcilazo-Reyes, Alexandra;
    • Rosell, Rafael
    Publication type:
    Article
    49
    50